Detail akcie AnPac Bio Sp ADR-A online

Business Summary: Fresh2 Group Ltd, formerly AnPac Bio-Medical Science Co Ltd, is a holding company mainly engaged in early cancer screening and detection. The Company is engaged in marketing and selling multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. The Company's CDA technology also assists physicians in cancer diagnosis, prognosis and recurrence. The Company provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, Internet, and Web3 transformation of start-ups and traditional enterprises.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Fresh2 Group Ltd - ADR revenues increased from RMB2M to RMB4.9M. Net loss before extraordinary items increased from RMB7.1M to RMB43.5M. Revenues reflect China (Mainland) segment increase from RMB0K to RMB4.9M. Higher net loss reflects China (Mainland) segment loss increase from RMB8.6M to RMB43.2M. Basic Earnings per Share excluding Extraordinary Items increased from -RMB5.93 to -RMB4.26.